Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

Cancer

Volumn 94, Issue 2, 2002, Pages 435-442

  Sakon, Masato ^a   Nagano, Hiroaki ^a   Dono, Keizo ^a   Nakamori, Shoji ^a   Umeshita, Koji ^a   Yamada, Akira ^a   Kawata, Sumio ^a   Imai, Yasuharu ^b   Iijima, Shohei ^c   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b IKEDA MUNICIPAL HOSPITAL   (Japan)

^c Shitennoji University   (Japan)

Author keywords

5 fluorouracil; Chemotherapy; Hepatocellular carcinoma; Interferon ; Portal vein; Tumor thrombus

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; OIF; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; INTERMETHOD COMPARISON; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR THROMBUS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON-ALPHA; LEUKOPENIA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PORTAL VEIN; PROGNOSIS; REMISSION INDUCTION; THROMBOCYTOPENIA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0037080269     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10246     Document Type: Article

References (27)

1. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma
2. Intra-arterial intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma a randomized comparison
3. Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma
4. Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma
5. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: A pilot study
6. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma
7. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
8. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial
9. Viral serostatus and coexisting inflammatory activity affect metachronous carcinogenesis after hepatectomy for hepatocellular carcinoma. A further report
10. Recombinant leukocyte A interferon with doxorubicin: A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma
11. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma
12. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma
13. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
14. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis
15. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins
16. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines
17. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes
18. Spontaneous cell-mediated cytotoxicity in humans; role of interferon and immunoglobulins
19. Combination therapy with 5-fluorouracil and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells
20. Synergistic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells
21. Inhibition of angiogenesis
22. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
23. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration
24. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
25. Interferon effects upon fluorouracil metabolism by HL-60 cells
26. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells
27. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b